Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support

A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

C. Tarella, M. Zanni, M. Di Nicola, C. Patti, R. Calvi, A. Pescarollo, V. Zoli, A. Fornari, D. Novero, A. Cabras, M. Stella, A. Comino, D. Remotti, M. Ponzoni, D. Caracciolo, M. Ladetto, M. Magni, L. Devizzi, R. Rosato, M. Boccadoro & 6 others M. Bregni, P. Corradini, A. Gallamini, I. Majolino, S. Mirto, A. M. Gianni

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged

Original languageEnglish
Pages (from-to)1802-1811
Number of pages10
JournalLeukemia
Volume21
Issue number8
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Cytarabine
Hematopoietic Stem Cells
Multicenter Studies
Blood Cells
Stem Cells
Etoposide
Drug Therapy
Cisplatin
Survival
Mitoxantrone
Cyclophosphamide
Radiotherapy
Therapeutics
Rituximab

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support : A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). / Tarella, C.; Zanni, M.; Di Nicola, M.; Patti, C.; Calvi, R.; Pescarollo, A.; Zoli, V.; Fornari, A.; Novero, D.; Cabras, A.; Stella, M.; Comino, A.; Remotti, D.; Ponzoni, M.; Caracciolo, D.; Ladetto, M.; Magni, M.; Devizzi, L.; Rosato, R.; Boccadoro, M.; Bregni, M.; Corradini, P.; Gallamini, A.; Majolino, I.; Mirto, S.; Gianni, A. M.

In: Leukemia, Vol. 21, No. 8, 08.2007, p. 1802-1811.

Research output: Contribution to journalArticle

Tarella, C, Zanni, M, Di Nicola, M, Patti, C, Calvi, R, Pescarollo, A, Zoli, V, Fornari, A, Novero, D, Cabras, A, Stella, M, Comino, A, Remotti, D, Ponzoni, M, Caracciolo, D, Ladetto, M, Magni, M, Devizzi, L, Rosato, R, Boccadoro, M, Bregni, M, Corradini, P, Gallamini, A, Majolino, I, Mirto, S & Gianni, AM 2007, 'Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)', Leukemia, vol. 21, no. 8, pp. 1802-1811. https://doi.org/10.1038/sj.leu.2404781
Tarella, C. ; Zanni, M. ; Di Nicola, M. ; Patti, C. ; Calvi, R. ; Pescarollo, A. ; Zoli, V. ; Fornari, A. ; Novero, D. ; Cabras, A. ; Stella, M. ; Comino, A. ; Remotti, D. ; Ponzoni, M. ; Caracciolo, D. ; Ladetto, M. ; Magni, M. ; Devizzi, L. ; Rosato, R. ; Boccadoro, M. ; Bregni, M. ; Corradini, P. ; Gallamini, A. ; Majolino, I. ; Mirto, S. ; Gianni, A. M. / Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support : A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). In: Leukemia. 2007 ; Vol. 21, No. 8. pp. 1802-1811.
@article{ad5d5332a0144f05b69d08cf1b3e56fe,
title = "Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)",
abstract = "A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged",
author = "C. Tarella and M. Zanni and {Di Nicola}, M. and C. Patti and R. Calvi and A. Pescarollo and V. Zoli and A. Fornari and D. Novero and A. Cabras and M. Stella and A. Comino and D. Remotti and M. Ponzoni and D. Caracciolo and M. Ladetto and M. Magni and L. Devizzi and R. Rosato and M. Boccadoro and M. Bregni and P. Corradini and A. Gallamini and I. Majolino and S. Mirto and Gianni, {A. M.}",
year = "2007",
month = "8",
doi = "10.1038/sj.leu.2404781",
language = "English",
volume = "21",
pages = "1802--1811",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support

T2 - A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

AU - Tarella, C.

AU - Zanni, M.

AU - Di Nicola, M.

AU - Patti, C.

AU - Calvi, R.

AU - Pescarollo, A.

AU - Zoli, V.

AU - Fornari, A.

AU - Novero, D.

AU - Cabras, A.

AU - Stella, M.

AU - Comino, A.

AU - Remotti, D.

AU - Ponzoni, M.

AU - Caracciolo, D.

AU - Ladetto, M.

AU - Magni, M.

AU - Devizzi, L.

AU - Rosato, R.

AU - Boccadoro, M.

AU - Bregni, M.

AU - Corradini, P.

AU - Gallamini, A.

AU - Majolino, I.

AU - Mirto, S.

AU - Gianni, A. M.

PY - 2007/8

Y1 - 2007/8

N2 - A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged

AB - A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged

UR - http://www.scopus.com/inward/record.url?scp=34447626101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447626101&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404781

DO - 10.1038/sj.leu.2404781

M3 - Article

VL - 21

SP - 1802

EP - 1811

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -